Sanuwave Health (SNWV) Registration Filing summary

Company overview and business model

• Specializes in noninvasive ultrasound and shock wave systems for regenerative medicine, focusing on wound healing and tissue regeneration.

• Primary products include UltraMIST (low-frequency, non-contact ultrasound) and PACE (acoustic pressure shockwave), both FDA-cleared for wound healing.

• UltraMIST is marketed in the U.S.; PACE systems are marketed in the U.S. and select international markets.

• Ongoing product development includes antibacterial solutions, new applicators, and expanded indications in orthopedics, aesthetics, and cardiovascular applications.

Financial performance and metrics

• Recent private placements in December 2023, January 2024, June 2024, and October 2024 raised approximately $1.8M, $0, $1.3M, and $10.3M, respectively.

• Notes issued in these placements carried a 15% annual interest rate and were convertible into common stock.

• A reverse stock split (1:375) was effected on October 18, 2024.

• The last reported sale price of common stock on November 29, 2024, was $21.00 per share.

Use of proceeds and capital allocation

• All net proceeds from the sale of shares in this offering will go to the selling stockholders; the company will not receive any proceeds.